Novacyt S.A. (NVYTF) Shareholder/Analyst Call Prepared Remarks Transcript

Lyn Rees
CEO & Executive Director

Good morning, everyone, and welcome to our 2026 AGM Management Presentation. As ever, I’d like to thank all shareholders in the room with us today in Paris and joining us remotely for your continued support.

The presentation team today is myself and Steve. We’re going to be talking through some of the highlights of the 2025 period, updating you on some post-period events and talking through the numbers as ever.

So before we do that, I thought we’d just jump into a quick update of the Novacyt Group. A lot of you have seen this slide before. The new addition is the Southern Cross Diagnostics logo in the middle of that diagram.

As an organization, we’re an international molecular diagnostics company with a portfolio of clinical assays, instrumentation and research tools. We focus predominantly in reproductive health care, precision medicine and infectious disease. And when you look at the diagram, basically Yourgene Health, the box on the left-hand side is all of the clinical IVD assays, anything to do with DNA size selection, our range of technology and all of our products in this space have to go through the IVDR regulatory approval.

The middle box is our newly acquired Southern Cross Diagnostics business, a distributor of life science products, which gives us more opportunity to sell third-party products throughout our organization. And then we have on the right-hand side, Primerdesign, which is a bit of a cash cow, very high-margin business, nonregulated, so in the research use market space only, where we’re selling qPCR kits for pathogen detection in things like infectious disease, veterinary, et cetera.